271 related articles for article (PubMed ID: 33338730)
21. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
[TBL] [Abstract][Full Text] [Related]
22. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
23. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.
Busca C; Sánchez-Conde M; Rico M; Rosas M; Valencia E; Moreno A; Moreno V; Martín-Carbonero L; Moreno S; Pérez-Valero I; Bernardino JI; Arribas JR; González J; Olveira A; Castillo P; Abadía M; Guerra L; Mendez C; Montes ML
Open Forum Infect Dis; 2022 Jul; 9(7):ofac279. PubMed ID: 35873289
[TBL] [Abstract][Full Text] [Related]
25. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
27. Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting.
Jung TY; Kim MS; Hong HP; Kang KA; Jun DW
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899243
[TBL] [Abstract][Full Text] [Related]
28. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy.
Chang JW; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Gut Liver; 2021 Jan; 15(1):117-127. PubMed ID: 32066210
[TBL] [Abstract][Full Text] [Related]
29. Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults on their health check-up.
Zeng J; Sun C; Sun WL; Chen GY; Pan Q; Yan SY; Xu ZJ; Chen YW; Fan JG
J Dig Dis; 2017 Apr; 18(4):229-236. PubMed ID: 28296249
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
[TBL] [Abstract][Full Text] [Related]
31. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.
Zhang B; Ding F; Chen T; Xia LH; Qian J; Lv GY
World J Gastroenterol; 2014 Dec; 20(47):17985-92. PubMed ID: 25548498
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
[TBL] [Abstract][Full Text] [Related]
33. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
34. A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease.
Chen LW; Huang PR; Chien CH; Lin CL; Chien RN
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):173-181. PubMed ID: 30981560
[TBL] [Abstract][Full Text] [Related]
35. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases.
Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Targher G; Lonardo A
Metabolism; 2017 Jul; 72():57-65. PubMed ID: 28641784
[TBL] [Abstract][Full Text] [Related]
36. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique.
Bae JS; Lee DH; Lee JY; Kim H; Yu SJ; Lee JH; Cho EJ; Lee YB; Han JK; Choi BI
Eur Radiol; 2019 Dec; 29(12):6499-6507. PubMed ID: 31175413
[TBL] [Abstract][Full Text] [Related]
37. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population.
Nelson SM; Hoskins JD; Lisanti C; Chaudhuri J
J Ultrasound Med; 2020 Apr; 39(4):749-759. PubMed ID: 31647137
[TBL] [Abstract][Full Text] [Related]
38. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
39. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease.
Pirmoazen AM; Khurana A; El Kaffas A; Kamaya A
Theranostics; 2020; 10(9):4277-4289. PubMed ID: 32226553
[TBL] [Abstract][Full Text] [Related]
40. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
